Immunotherapy combo aims to stop cervical cancer in its tracks
NCT ID NCT07340489
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether adding the immunotherapy drug serplulimab to standard chemoradiotherapy can help people with locally advanced cervical cancer live longer without their disease getting worse. About 216 participants who have not yet been treated will receive either chemoradiotherapy alone or with serplulimab. The study will track how long it takes for the cancer to progress and monitor any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- serplulimab (an immunotherapy drug) plus standard chemoradiotherapy (radiation and chemotherapy)
- What this could lead to
- If it works, this could lead to a new treatment option that helps keep cervical cancer from growing or coming back for longer.
- What could go wrong
- This is an early phase II trial with only 216 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital,
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment